Table of Content

1 Report Overview
1.1 Antidiabetic Drug Definition
1.2 Market by Type
1.2.1 Global Antidiabetic Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Alpha-Glucosidase Inhibitors
1.2.3 Biguanides, Sulphonylureas
1.2.4 Glp-1 Agonist
1.2.5 Meglitinides
1.2.6 Dpp-4 Inhibitors
1.2.7 Sglt–2
1.2.8 Thiazolodinediones
1.3 Market Segment by Application
1.3.1 Global Antidiabetic Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Type I Diabetes
1.3.3 Type II Diabetes
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Antidiabetic Drug Sales
2.1 Global Antidiabetic Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Antidiabetic Drug Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Antidiabetic Drug Revenue by Region
2.3.1 Global Antidiabetic Drug Revenue by Region (2018-2023)
2.3.2 Global Antidiabetic Drug Revenue by Region (2024-2034)
2.4 Global Antidiabetic Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Antidiabetic Drug Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Antidiabetic Drug Sales Quantity by Region
2.6.1 Global Antidiabetic Drug Sales Quantity by Region (2018-2023)
2.6.2 Global Antidiabetic Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Antidiabetic Drug Sales Quantity by Manufacturers
3.1.1 Global Antidiabetic Drug Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Antidiabetic Drug Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Antidiabetic Drug Sales in 2024
3.2 Global Antidiabetic Drug Revenue by Manufacturers
3.2.1 Global Antidiabetic Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Antidiabetic Drug Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Antidiabetic Drug Revenue in 2024
3.3 Global Antidiabetic Drug Sales Price by Manufacturers
3.4 Global Key Players of Antidiabetic Drug, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Antidiabetic Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Antidiabetic Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Antidiabetic Drug, Product Offered and Application
3.8 Global Key Manufacturers of Antidiabetic Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Antidiabetic Drug Sales Quantity by Type
4.1.1 Global Antidiabetic Drug Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Antidiabetic Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Antidiabetic Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Antidiabetic Drug Revenue by Type
4.2.1 Global Antidiabetic Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Antidiabetic Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Antidiabetic Drug Revenue Market Share by Type (2018-2034)
4.3 Global Antidiabetic Drug Price by Type
4.3.1 Global Antidiabetic Drug Price by Type (2018-2023)
4.3.2 Global Antidiabetic Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Antidiabetic Drug Sales Quantity by Application
5.1.1 Global Antidiabetic Drug Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Antidiabetic Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Antidiabetic Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Antidiabetic Drug Revenue by Application
5.2.1 Global Antidiabetic Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Antidiabetic Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Antidiabetic Drug Revenue Market Share by Application (2018-2034)
5.3 Global Antidiabetic Drug Price by Application
5.3.1 Global Antidiabetic Drug Price by Application (2018-2023)
5.3.2 Global Antidiabetic Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Antidiabetic Drug Sales by Company
6.1.1 North America Antidiabetic Drug Revenue by Company (2018-2023)
6.1.2 North America Antidiabetic Drug Sales Quantity by Company (2018-2023)
6.2 North America Antidiabetic Drug Market Size by Type
6.2.1 North America Antidiabetic Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Antidiabetic Drug Revenue by Type (2018-2034)
6.3 North America Antidiabetic Drug Market Size by Application
6.3.1 North America Antidiabetic Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Antidiabetic Drug Revenue by Application (2018-2034)
6.4 North America Antidiabetic Drug Market Size by Country
6.4.1 North America Antidiabetic Drug Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Antidiabetic Drug Revenue by Country (2018-2034)
6.4.3 North America Antidiabetic Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Antidiabetic Drug Sales by Company
7.1.1 Europe Antidiabetic Drug Sales Quantity by Company (2018-2023)
7.1.2 Europe Antidiabetic Drug Revenue by Company (2018-2023)
7.2 Europe Antidiabetic Drug Market Size by Type
7.2.1 Europe Antidiabetic Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Antidiabetic Drug Revenue by Type (2018-2034)
7.3 Europe Antidiabetic Drug Market Size by Application
7.3.1 Europe Antidiabetic Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Antidiabetic Drug Revenue by Application (2018-2034)
7.4 Europe Antidiabetic Drug Market Size by Country
7.4.1 Europe Antidiabetic Drug Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Antidiabetic Drug Revenue by Country (2018-2034)
7.4.3 Europe Antidiabetic Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Antidiabetic Drug Sales by Company
8.1.1 China Antidiabetic Drug Sales Quantity by Company (2018-2023)
8.1.2 China Antidiabetic Drug Revenue by Company (2018-2023)
8.2 China Antidiabetic Drug Market Size by Type
8.2.1 China Antidiabetic Drug Sales Quantity by Type (2018-2034)
8.2.2 China Antidiabetic Drug Revenue by Type (2018-2034)
8.3 China Antidiabetic Drug Market Size by Application
8.3.1 China Antidiabetic Drug Sales Quantity by Application (2018-2034)
8.3.2 China Antidiabetic Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Antidiabetic Drug Sales by Company
9.1.1 APAC Antidiabetic Drug Sales Quantity by Company (2018-2023)
9.1.2 APAC Antidiabetic Drug Revenue by Company (2018-2023)
9.2 APAC Antidiabetic Drug Market Size by Type
9.2.1 APAC Antidiabetic Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Antidiabetic Drug Revenue by Type (2018-2034)
9.3 APAC Antidiabetic Drug Market Size by Application
9.3.1 APAC Antidiabetic Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Antidiabetic Drug Revenue by Application (2018-2034)
9.4 APAC Antidiabetic Drug Market Size by Region
9.4.1 APAC Antidiabetic Drug Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Antidiabetic Drug Revenue by Region (2018-2034)
9.4.3 APAC Antidiabetic Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Antidiabetic Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Antidiabetic Drug Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Antidiabetic Drug Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Antidiabetic Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Antidiabetic Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Antidiabetic Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Antidiabetic Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Antidiabetic Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Antidiabetic Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Antidiabetic Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Antidiabetic Drug Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Antidiabetic Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Antidiabetic Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Sanofi-Aventis
11.1.1 Sanofi-Aventis Company Information
11.1.2 Sanofi-Aventis Overview
11.1.3 Sanofi-Aventis Antidiabetic Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Sanofi-Aventis Antidiabetic Drug Products and Services
11.1.5 Sanofi-Aventis Antidiabetic Drug SWOT Analysis
11.1.6 Sanofi-Aventis Recent Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Company Information
11.2.2 Eli Lilly Overview
11.2.3 Eli Lilly Antidiabetic Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Eli Lilly Antidiabetic Drug Products and Services
11.2.5 Eli Lilly Antidiabetic Drug SWOT Analysis
11.2.6 Eli Lilly Recent Developments
11.3 Oramed
11.3.1 Oramed Company Information
11.3.2 Oramed Overview
11.3.3 Oramed Antidiabetic Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Oramed Antidiabetic Drug Products and Services
11.3.5 Oramed Antidiabetic Drug SWOT Analysis
11.3.6 Oramed Recent Developments
11.4 Takeda
11.4.1 Takeda Company Information
11.4.2 Takeda Overview
11.4.3 Takeda Antidiabetic Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Takeda Antidiabetic Drug Products and Services
11.4.5 Takeda Antidiabetic Drug SWOT Analysis
11.4.6 Takeda Recent Developments
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Information
11.5.2 Boehringer Ingelheim Overview
11.5.3 Boehringer Ingelheim Antidiabetic Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Boehringer Ingelheim Antidiabetic Drug Products and Services
11.5.5 Boehringer Ingelheim Antidiabetic Drug SWOT Analysis
11.5.6 Boehringer Ingelheim Recent Developments
11.6 Novo Nordisk
11.6.1 Novo Nordisk Company Information
11.6.2 Novo Nordisk Overview
11.6.3 Novo Nordisk Antidiabetic Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Novo Nordisk Antidiabetic Drug Products and Services
11.6.5 Novo Nordisk Antidiabetic Drug SWOT Analysis
11.6.6 Novo Nordisk Recent Developments
11.7 Halozyme Therapeutics
11.7.1 Halozyme Therapeutics Company Information
11.7.2 Halozyme Therapeutics Overview
11.7.3 Halozyme Therapeutics Antidiabetic Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Halozyme Therapeutics Antidiabetic Drug Products and Services
11.7.5 Halozyme Therapeutics Antidiabetic Drug SWOT Analysis
11.7.6 Halozyme Therapeutics Recent Developments
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Information
11.8.2 Bristol-Myers Squibb Overview
11.8.3 Bristol-Myers Squibb Antidiabetic Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Bristol-Myers Squibb Antidiabetic Drug Products and Services
11.8.5 Bristol-Myers Squibb Antidiabetic Drug SWOT Analysis
11.8.6 Bristol-Myers Squibb Recent Developments
11.9 Pfizer
11.9.1 Pfizer Company Information
11.9.2 Pfizer Overview
11.9.3 Pfizer Antidiabetic Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Pfizer Antidiabetic Drug Products and Services
11.9.5 Pfizer Antidiabetic Drug SWOT Analysis
11.9.6 Pfizer Recent Developments
11.10 Tonghua Dongbao
11.10.1 Tonghua Dongbao Company Information
11.10.2 Tonghua Dongbao Overview
11.10.3 Tonghua Dongbao Antidiabetic Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 Tonghua Dongbao Antidiabetic Drug Products and Services
11.10.5 Tonghua Dongbao Antidiabetic Drug SWOT Analysis
11.10.6 Tonghua Dongbao Recent Developments
11.11 Biocon
11.11.1 Biocon Company Information
11.11.2 Biocon Overview
11.11.3 Biocon Antidiabetic Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.11.4 Biocon Antidiabetic Drug Products and Services
11.11.5 Biocon Recent Developments
11.12 Wockhardt
11.12.1 Wockhardt Company Information
11.12.2 Wockhardt Overview
11.12.3 Wockhardt Antidiabetic Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.12.4 Wockhardt Antidiabetic Drug Products and Services
11.12.5 Wockhardt Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Antidiabetic Drug Value Chain Analysis
12.2 Antidiabetic Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Antidiabetic Drug Production Mode & Process
12.4 Antidiabetic Drug Sales and Marketing
12.4.1 Antidiabetic Drug Sales Channels
12.4.2 Antidiabetic Drug Distributors
12.5 Antidiabetic Drug Customers
13 Market Dynamics
13.1 Antidiabetic Drug Industry Trends
13.2 Antidiabetic Drug Market Drivers
13.3 Antidiabetic Drug Market Challenges
13.4 Antidiabetic Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Antidiabetic Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Alpha-Glucosidase Inhibitors
Table 3. Major Manufacturers of Biguanides, Sulphonylureas
Table 4. Major Manufacturers of Glp-1 Agonist
Table 5. Major Manufacturers of Meglitinides
Table 6. Major Manufacturers of Dpp-4 Inhibitors
Table 7. Major Manufacturers of Sglt–2
Table 8. Major Manufacturers of Thiazolodinediones
Table 9. Global Antidiabetic Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Antidiabetic Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 11. Global Antidiabetic Drug Revenue by Region (2018-2023) & (US$ Million)
Table 12. Global Antidiabetic Drug Revenue Market Share by Region (2018-2023)
Table 13. Global Antidiabetic Drug Revenue by Region (2024-2034) & (US$ Million)
Table 14. Global Antidiabetic Drug Revenue Market Share by Region (2024-2034)
Table 15. Global Antidiabetic Drug Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Units)
Table 16. Global Antidiabetic Drug Sales by Region (2018-2023) & (K Units)
Table 17. Global Antidiabetic Drug Sales Market Share by Region (2018-2023)
Table 18. Global Antidiabetic Drug Sales by Region (2024-2034) & (K Units)
Table 19. Global Antidiabetic Drug Sales Market Share by Region (2024-2034)
Table 20. Global Antidiabetic Drug Sales Quantity by Manufacturers (2018-2023) & (K Units)
Table 21. Global Antidiabetic Drug Sales Quantity Share by Manufacturers (2018-2023)
Table 22. Global Antidiabetic Drug Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 23. Global Antidiabetic Drug Revenue Share by Manufacturers (2018-2023)
Table 24. Global Antidiabetic Drug Price by Manufacturers 2018-2023 (USD/Unit)
Table 25. Global Key Players of Antidiabetic Drug, Industry Ranking, 2021 VS 2024
Table 26. Global Antidiabetic Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 27. Global Antidiabetic Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antidiabetic Drug as of 2024)
Table 28. Global Key Manufacturers of Antidiabetic Drug, Manufacturing Base Distribution and Headquarters
Table 29. Global Key Manufacturers of Antidiabetic Drug, Product Offered and Application
Table 30. Global Key Manufacturers of Antidiabetic Drug, Date of Enter into This Industry
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global Antidiabetic Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 33. Global Antidiabetic Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 34. Global Antidiabetic Drug Sales Quantity Share by Type (2018-2023)
Table 35. Global Antidiabetic Drug Sales Quantity Share by Type (2024-2034)
Table 36. Global Antidiabetic Drug Revenue by Type (2018-2023) & (US$ Million)
Table 37. Global Antidiabetic Drug Revenue by Type (2024-2034) & (US$ Million)
Table 38. Global Antidiabetic Drug Revenue Share by Type (2018-2023)
Table 39. Global Antidiabetic Drug Revenue Share by Type (2024-2034)
Table 40. Antidiabetic Drug Price by Type (2018-2023) & (USD/Unit)
Table 41. Global Antidiabetic Drug Price Forecast by Type (2024-2034) & (USD/Unit)
Table 42. Global Antidiabetic Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 43. Global Antidiabetic Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 44. Global Antidiabetic Drug Sales Quantity Share by Application (2018-2023)
Table 45. Global Antidiabetic Drug Sales Quantity Share by Application (2024-2034)
Table 46. Global Antidiabetic Drug Revenue by Application (2018-2023) & (US$ Million)
Table 47. Global Antidiabetic Drug Revenue by Application (2024-2034) & (US$ Million)
Table 48. Global Antidiabetic Drug Revenue Share by Application (2018-2023)
Table 49. Global Antidiabetic Drug Revenue Share by Application (2024-2034)
Table 50. Antidiabetic Drug Price by Application (2018-2023) & (USD/Unit)
Table 51. Global Antidiabetic Drug Price Forecast by Application (2024-2034) & (USD/Unit)
Table 52. North America Antidiabetic Drug Revenue by Company (2018-2023) & (US$ Million)
Table 53. North America Antidiabetic Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 54. North America Antidiabetic Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 55. North America Antidiabetic Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 56. North America Antidiabetic Drug Revenue by Type (2018-2023) & (US$ Million)
Table 57. North America Antidiabetic Drug Revenue by Type (2024-2034) & (US$ Million)
Table 58. North America Antidiabetic Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 59. North America Antidiabetic Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 60. North America Antidiabetic Drug Revenue by Application (2018-2023) & (US$ Million)
Table 61. North America Antidiabetic Drug Revenue by Application (2024-2034) & (US$ Million)
Table 62. North America Antidiabetic Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 63. North America Antidiabetic Drug Revenue by Country (2018-2023) & (US$ Million)
Table 64. North America Antidiabetic Drug Revenue by Country (2024-2034) & (US$ Million)
Table 65. North America Antidiabetic Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 66. North America Antidiabetic Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 67. Europe Antidiabetic Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 68. Europe Antidiabetic Drug Revenue by Company (2018-2023) & (US$ Million)
Table 69. Europe Antidiabetic Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 70. Europe Antidiabetic Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 71. Europe Antidiabetic Drug Revenue by Type (2018-2023) & (US$ Million)
Table 72. Europe Antidiabetic Drug Revenue by Type (2024-2034) & (US$ Million)
Table 73. Europe Antidiabetic Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 74. Europe Antidiabetic Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 75. Europe Antidiabetic Drug Revenue by Application (2018-2023) & (US$ Million)
Table 76. Europe Antidiabetic Drug Revenue by Application (2024-2034) & (US$ Million)
Table 77. Europe Antidiabetic Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 78. Europe Antidiabetic Drug Revenue by Country (2018-2023) & (US$ Million)
Table 79. Europe Antidiabetic Drug Revenue by Country (2024-2034) & (US$ Million)
Table 80. Europe Antidiabetic Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 81. Europe Antidiabetic Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 82. China Antidiabetic Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 83. China Antidiabetic Drug Revenue by Company (2018-2023) & (US$ Million)
Table 84. China Antidiabetic Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 85. China Antidiabetic Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 86. China Antidiabetic Drug Revenue by Type (2018-2023) & (US$ Million)
Table 87. China Antidiabetic Drug Revenue by Type (2024-2034) & (US$ Million)
Table 88. China Antidiabetic Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 89. China Antidiabetic Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 90. China Antidiabetic Drug Revenue by Application (2018-2023) & (US$ Million)
Table 91. China Antidiabetic Drug Revenue by Application (2024-2034) & (US$ Million)
Table 92. APAC Antidiabetic Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 93. APAC Antidiabetic Drug Revenue by Company (2018-2023) & (US$ Million)
Table 94. APAC Antidiabetic Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 95. APAC Antidiabetic Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 96. APAC Antidiabetic Drug Revenue by Type (2018-2023) & (US$ Million)
Table 97. APAC Antidiabetic Drug Revenue by Type (2024-2034) & (US$ Million)
Table 98. APAC Antidiabetic Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 99. APAC Antidiabetic Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 100. APAC Antidiabetic Drug Revenue by Application (2018-2023) & (US$ Million)
Table 101. APAC Antidiabetic Drug Revenue by Application (2024-2034) & (US$ Million)
Table 102. APAC Antidiabetic Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 103. APAC Antidiabetic Drug Revenue by Region (2018-2023) & (US$ Million)
Table 104. APAC Antidiabetic Drug Revenue by Region (2024-2034) & (US$ Million)
Table 105. APAC Antidiabetic Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 106. APAC Antidiabetic Drug Sales Quantity by Region (2024-2034) & (K Units)
Table 107. Middle East, Africa and Latin America Antidiabetic Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 108. Middle East, Africa and Latin America Antidiabetic Drug Revenue by Company (2018-2023) & (US$ Million)
Table 109. Middle East, Africa and Latin America Antidiabetic Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 110. Middle East, Africa and Latin America Antidiabetic Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 111. Middle East, Africa and Latin America Antidiabetic Drug Revenue by Type (2018-2023) & (US$ Million)
Table 112. Middle East, Africa and Latin America Antidiabetic Drug Revenue by Type (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Antidiabetic Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 114. Middle East, Africa and Latin America Antidiabetic Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 115. Middle East, Africa and Latin America Antidiabetic Drug Revenue by Application (2018-2023) & (US$ Million)
Table 116. Middle East, Africa and Latin America Antidiabetic Drug Revenue by Application (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Antidiabetic Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 118. Middle East, Africa and Latin America Antidiabetic Drug Revenue by Country (2018-2023) & (US$ Million)
Table 119. Middle East, Africa and Latin America Antidiabetic Drug Revenue by Country (2024-2034) & (US$ Million)
Table 120. Middle East, Africa and Latin America Antidiabetic Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 121. Middle East, Africa and Latin America Antidiabetic Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 122. Sanofi-Aventis Company Information
Table 123. Sanofi-Aventis Description and Overview
Table 124. Sanofi-Aventis Antidiabetic Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 125. Sanofi-Aventis Antidiabetic Drug Product and Services
Table 126. Sanofi-Aventis Antidiabetic Drug SWOT Analysis
Table 127. Sanofi-Aventis Recent Developments
Table 128. Eli Lilly Company Information
Table 129. Eli Lilly Description and Overview
Table 130. Eli Lilly Antidiabetic Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 131. Eli Lilly Antidiabetic Drug Product and Services
Table 132. Eli Lilly Antidiabetic Drug SWOT Analysis
Table 133. Eli Lilly Recent Developments
Table 134. Oramed Company Information
Table 135. Oramed Description and Overview
Table 136. Oramed Antidiabetic Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 137. Oramed Antidiabetic Drug Product and Services
Table 138. Oramed Antidiabetic Drug SWOT Analysis
Table 139. Oramed Recent Developments
Table 140. Takeda Company Information
Table 141. Takeda Description and Overview
Table 142. Takeda Antidiabetic Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 143. Takeda Antidiabetic Drug Product and Services
Table 144. Takeda Antidiabetic Drug SWOT Analysis
Table 145. Takeda Recent Developments
Table 146. Boehringer Ingelheim Company Information
Table 147. Boehringer Ingelheim Description and Overview
Table 148. Boehringer Ingelheim Antidiabetic Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 149. Boehringer Ingelheim Antidiabetic Drug Product and Services
Table 150. Boehringer Ingelheim Antidiabetic Drug SWOT Analysis
Table 151. Boehringer Ingelheim Recent Developments
Table 152. Novo Nordisk Company Information
Table 153. Novo Nordisk Description and Overview
Table 154. Novo Nordisk Antidiabetic Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 155. Novo Nordisk Antidiabetic Drug Product and Services
Table 156. Novo Nordisk Antidiabetic Drug SWOT Analysis
Table 157. Novo Nordisk Recent Developments
Table 158. Halozyme Therapeutics Company Information
Table 159. Halozyme Therapeutics Description and Overview
Table 160. Halozyme Therapeutics Antidiabetic Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 161. Halozyme Therapeutics Antidiabetic Drug Product and Services
Table 162. Halozyme Therapeutics Antidiabetic Drug SWOT Analysis
Table 163. Halozyme Therapeutics Recent Developments
Table 164. Bristol-Myers Squibb Company Information
Table 165. Bristol-Myers Squibb Description and Overview
Table 166. Bristol-Myers Squibb Antidiabetic Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 167. Bristol-Myers Squibb Antidiabetic Drug Product and Services
Table 168. Bristol-Myers Squibb Antidiabetic Drug SWOT Analysis
Table 169. Bristol-Myers Squibb Recent Developments
Table 170. Pfizer Company Information
Table 171. Pfizer Description and Overview
Table 172. Pfizer Antidiabetic Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 173. Pfizer Antidiabetic Drug Product and Services
Table 174. Pfizer Antidiabetic Drug SWOT Analysis
Table 175. Pfizer Recent Developments
Table 176. Tonghua Dongbao Company Information
Table 177. Tonghua Dongbao Description and Overview
Table 178. Tonghua Dongbao Antidiabetic Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 179. Tonghua Dongbao Antidiabetic Drug Product and Services
Table 180. Tonghua Dongbao Antidiabetic Drug SWOT Analysis
Table 181. Tonghua Dongbao Recent Developments
Table 182. Biocon Company Information
Table 183. Biocon Description and Overview
Table 184. Biocon Antidiabetic Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 185. Biocon Antidiabetic Drug Product and Services
Table 186. Biocon Recent Developments
Table 187. Wockhardt Company Information
Table 188. Wockhardt Description and Overview
Table 189. Wockhardt Antidiabetic Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 190. Wockhardt Antidiabetic Drug Product and Services
Table 191. Wockhardt Recent Developments
Table 192. Key Raw Materials Lists
Table 193. Raw Materials Key Suppliers Lists
Table 194. Antidiabetic Drug Distributors List
Table 195. Antidiabetic Drug Customers List
Table 196. Antidiabetic Drug Market Trends
Table 197. Antidiabetic Drug Market Drivers
Table 198. Antidiabetic Drug Market Challenges
Table 199. Antidiabetic Drug Market Restraints
Table 200. Research Programs/Design for This Report
Table 201. Key Data Information from Secondary Sources
Table 202. Key Data Information from Primary Sources
List of Figures
Figure 1. Antidiabetic Drug Product Picture
Figure 2. Global Antidiabetic Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Antidiabetic Drug Market Share by Type in 2024 & 2034
Figure 4. Alpha-Glucosidase Inhibitors Product Picture
Figure 5. Biguanides, Sulphonylureas Product Picture
Figure 6. Glp-1 Agonist Product Picture
Figure 7. Meglitinides Product Picture
Figure 8. Dpp-4 Inhibitors Product Picture
Figure 9. Sglt–2 Product Picture
Figure 10. Thiazolodinediones Product Picture
Figure 11. Global Antidiabetic Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 12. Global Antidiabetic Drug Market Share by Application in 2024 & 2034
Figure 13. Type I Diabetes
Figure 14. Type II Diabetes
Figure 15. Antidiabetic Drug Report Years Considered
Figure 16. Global Antidiabetic Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 17. Global Antidiabetic Drug Revenue 2018-2034 (US$ Million)
Figure 18. Global Antidiabetic Drug Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 19. Global Antidiabetic Drug Sales Quantity 2018-2034 (K Units)
Figure 20. Global Antidiabetic Drug Sales Quantity Market Share by Region (2018-2023)
Figure 21. Global Antidiabetic Drug Sales Quantity Market Share by Region (2024-2034)
Figure 22. North America Antidiabetic Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. North America Antidiabetic Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 24. Europe Antidiabetic Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. Europe Antidiabetic Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 26. China Antidiabetic Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. China Antidiabetic Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 28. APAC Antidiabetic Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 29. APAC Antidiabetic Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 30. Middle East, Africa and Latin America Antidiabetic Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 31. Middle East, Africa and Latin America Antidiabetic Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 32. The Top 10 and Top 5 Players Market Share by Antidiabetic Drug Sales Quantity in 2024
Figure 33. The Top 10 and Top 5 Players Market Share by Antidiabetic Drug Revenue in 2024
Figure 34. Antidiabetic Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 35. Global Antidiabetic Drug Sales Quantity Market Share by Type (2018-2034)
Figure 36. Global Antidiabetic Drug Revenue Market Share by Type (2018-2034)
Figure 37. Global Antidiabetic Drug Sales Quantity Market Share by Application (2018-2034)
Figure 38. Global Antidiabetic Drug Revenue Market Share by Application (2018-2034)
Figure 39. North America Antidiabetic Drug Revenue Market Share by Company in 2024
Figure 40. North America Antidiabetic Drug Sales Quantity Market Share by Company in 2024
Figure 41. North America Antidiabetic Drug Sales Quantity Market Share by Type (2018-2034)
Figure 42. North America Antidiabetic Drug Revenue Market Share by Type (2018-2034)
Figure 43. North America Antidiabetic Drug Sales Quantity Market Share by Application (2018-2034)
Figure 44. North America Antidiabetic Drug Revenue Market Share by Application (2018-2034)
Figure 45. North America Antidiabetic Drug Revenue Share by Country (2018-2034)
Figure 46. North America Antidiabetic Drug Sales Quantity Share by Country (2018-2034)
Figure 47. U.S. Antidiabetic Drug Revenue (2018-2034) & (US$ Million)
Figure 48. Canada Antidiabetic Drug Revenue (2018-2034) & (US$ Million)
Figure 49. Europe Antidiabetic Drug Sales Quantity Market Share by Company in 2024
Figure 50. Europe Antidiabetic Drug Revenue Market Share by Company in 2024
Figure 51. Europe Antidiabetic Drug Sales Quantity Market Share by Type (2018-2034)
Figure 52. Europe Antidiabetic Drug Revenue Market Share by Type (2018-2034)
Figure 53. Europe Antidiabetic Drug Sales Quantity Market Share by Application (2018-2034)
Figure 54. Europe Antidiabetic Drug Revenue Market Share by Application (2018-2034)
Figure 55. Europe Antidiabetic Drug Revenue Share by Country (2018-2034)
Figure 56. Europe Antidiabetic Drug Sales Quantity Share by Country (2018-2034)
Figure 57. Germany Antidiabetic Drug Revenue (2018-2034) & (US$ Million)
Figure 58. France Antidiabetic Drug Revenue (2018-2034) & (US$ Million)
Figure 59. U.K. Antidiabetic Drug Revenue (2018-2034) & (US$ Million)
Figure 60. Italy Antidiabetic Drug Revenue (2018-2034) & (US$ Million)
Figure 61. Russia Antidiabetic Drug Revenue (2018-2034) & (US$ Million)
Figure 62. China Antidiabetic Drug Sales Quantity Market Share by Company in 2024
Figure 63. China Antidiabetic Drug Revenue Market Share by Company in 2024
Figure 64. China Antidiabetic Drug Sales Quantity Market Share by Type (2018-2034)
Figure 65. China Antidiabetic Drug Revenue Market Share by Type (2018-2034)
Figure 66. China Antidiabetic Drug Sales Quantity Market Share by Application (2018-2034)
Figure 67. China Antidiabetic Drug Revenue Market Share by Application (2018-2034)
Figure 68. APAC Antidiabetic Drug Sales Quantity Market Share by Company in 2024
Figure 69. APAC Antidiabetic Drug Revenue Market Share by Company in 2024
Figure 70. APAC Antidiabetic Drug Sales Quantity Market Share by Type (2018-2034)
Figure 71. APAC Antidiabetic Drug Revenue Market Share by Type (2018-2034)
Figure 72. APAC Antidiabetic Drug Sales Quantity Market Share by Application (2018-2034)
Figure 73. APAC Antidiabetic Drug Revenue Market Share by Application (2018-2034)
Figure 74. APAC Antidiabetic Drug Revenue Share by Region (2018-2034)
Figure 75. APAC Antidiabetic Drug Sales Quantity Share by Region (2018-2034)
Figure 76. Japan Antidiabetic Drug Revenue (2018-2034) & (US$ Million)
Figure 77. South Korea Antidiabetic Drug Revenue (2018-2034) & (US$ Million)
Figure 78. China Taiwan Antidiabetic Drug Revenue (2018-2034) & (US$ Million)
Figure 79. Southeast Asia Antidiabetic Drug Revenue (2018-2034) & (US$ Million)
Figure 80. India Antidiabetic Drug Revenue (2018-2034) & (US$ Million)
Figure 81. Middle East, Africa and Latin America Antidiabetic Drug Sales Quantity Market Share by Company in 2024
Figure 82. Middle East, Africa and Latin America Antidiabetic Drug Revenue Market Share by Company in 2024
Figure 83. Middle East, Africa and Latin America Antidiabetic Drug Sales Quantity Market Share by Type (2018-2034)
Figure 84. Middle East, Africa and Latin America Antidiabetic Drug Revenue Market Share by Type (2018-2034)
Figure 85. Middle East, Africa and Latin America Antidiabetic Drug Sales Quantity Market Share by Application (2018-2034)
Figure 86. Middle East, Africa and Latin America Antidiabetic Drug Revenue Market Share by Application (2018-2034)
Figure 87. Middle East, Africa and Latin America Antidiabetic Drug Sales Quantity Share by Country (2018-2034)
Figure 88. Middle East, Africa and Latin America Antidiabetic Drug Revenue Share by Country (2018-2034)
Figure 89. Brazil Antidiabetic Drug Revenue (2018-2034) & (US$ Million)
Figure 90. Mexico Antidiabetic Drug Revenue (2018-2034) & (US$ Million)
Figure 91. Turkey Antidiabetic Drug Revenue (2018-2034) & (US$ Million)
Figure 92. Israel Antidiabetic Drug Revenue (2018-2034) & (US$ Million)
Figure 93. GCC Countries Antidiabetic Drug Revenue (2018-2034) & (US$ Million)
Figure 94. Antidiabetic Drug Value Chain
Figure 95. Antidiabetic Drug Production Process
Figure 96. Channels of Distribution (Direct Vs Distribution)
Figure 97. Distributors Profiles
Figure 98. Bottom-up and Top-down Approaches for This Report
Figure 99. Data Triangulation
Figure 100. Key Executives Interviewed